KR102255403B1 - 결합된 광음향 및 초음파 진단 장치 및 방법 - Google Patents
결합된 광음향 및 초음파 진단 장치 및 방법 Download PDFInfo
- Publication number
- KR102255403B1 KR102255403B1 KR1020130085759A KR20130085759A KR102255403B1 KR 102255403 B1 KR102255403 B1 KR 102255403B1 KR 1020130085759 A KR1020130085759 A KR 1020130085759A KR 20130085759 A KR20130085759 A KR 20130085759A KR 102255403 B1 KR102255403 B1 KR 102255403B1
- Authority
- KR
- South Korea
- Prior art keywords
- photoacoustic
- signal
- microbubbles
- dye
- ultrasound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002604 ultrasonography Methods 0.000 title claims description 67
- 238000002405 diagnostic procedure Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 30
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims description 68
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 68
- 239000000975 dye Substances 0.000 claims description 66
- 150000002632 lipids Chemical class 0.000 claims description 57
- 239000007789 gas Substances 0.000 claims description 25
- 238000011049 filling Methods 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 12
- 238000012545 processing Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 claims description 7
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims description 7
- 229960004065 perflutren Drugs 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- 229960004657 indocyanine green Drugs 0.000 claims description 6
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims description 6
- -1 perluorodecane Chemical compound 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 5
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 4
- NFRFUGBXJTXTMZ-QYKZUBHNSA-L disodium;[(2r)-2,3-di(hexadecanoyloxy)propyl] phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])([O-])=O)OC(=O)CCCCCCCCCCCCCCC NFRFUGBXJTXTMZ-QYKZUBHNSA-L 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 claims description 3
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 claims description 3
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical group [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 claims description 3
- 229960003699 evans blue Drugs 0.000 claims description 3
- XJCPMUIIBDVFDM-UHFFFAOYSA-M nile blue A Chemical compound [Cl-].C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4[O+]=C3C=C(N)C2=C1 XJCPMUIIBDVFDM-UHFFFAOYSA-M 0.000 claims description 3
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000909 sulfur hexafluoride Drugs 0.000 claims description 3
- HRTBOPUWPUXROO-VCZQVZGSSA-N (2-{[(2r)-2,3-bis(docosanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC HRTBOPUWPUXROO-VCZQVZGSSA-N 0.000 claims description 2
- YKIOPDIXYAUOFN-YACUFSJGSA-N (2-{[(2r)-2,3-bis(icosanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC YKIOPDIXYAUOFN-YACUFSJGSA-N 0.000 claims description 2
- UVWPNDVAQBNQBG-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-icosafluorononane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F UVWPNDVAQBNQBG-UHFFFAOYSA-N 0.000 claims description 2
- CBEFDCMSEZEGCX-UHFFFAOYSA-N 1,1,2,2,2-pentafluoro-n,n-bis(1,1,2,2,2-pentafluoroethyl)ethanamine Chemical compound FC(F)(F)C(F)(F)N(C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)F CBEFDCMSEZEGCX-UHFFFAOYSA-N 0.000 claims description 2
- LZLVZIFMYXDKCN-QJWFYWCHSA-N 1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC LZLVZIFMYXDKCN-QJWFYWCHSA-N 0.000 claims description 2
- BIABMEZBCHDPBV-BEBVUIBBSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-BEBVUIBBSA-N 0.000 claims description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims description 2
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 claims description 2
- 229910018503 SF6 Inorganic materials 0.000 claims description 2
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 claims description 2
- WMIYKQLTONQJES-UHFFFAOYSA-N hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims description 2
- 229960004692 perflenapent Drugs 0.000 claims description 2
- 229960004624 perflexane Drugs 0.000 claims description 2
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 claims description 2
- 229960001217 perflubron Drugs 0.000 claims description 2
- LGUZHRODIJCVOC-UHFFFAOYSA-N perfluoroheptane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F LGUZHRODIJCVOC-UHFFFAOYSA-N 0.000 claims description 2
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 claims description 2
- YVBBRRALBYAZBM-UHFFFAOYSA-N perfluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YVBBRRALBYAZBM-UHFFFAOYSA-N 0.000 claims description 2
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 claims description 2
- ZQBFAOFFOQMSGJ-UHFFFAOYSA-N hexafluorobenzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1F ZQBFAOFFOQMSGJ-UHFFFAOYSA-N 0.000 claims 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical class CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims 1
- 238000003384 imaging method Methods 0.000 abstract description 55
- 239000002872 contrast media Substances 0.000 abstract description 21
- 239000000243 solution Substances 0.000 description 30
- 229940079593 drug Drugs 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 239000000523 sample Substances 0.000 description 14
- 238000012285 ultrasound imaging Methods 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 230000031700 light absorption Effects 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 238000009210 therapy by ultrasound Methods 0.000 description 6
- 238000003325 tomography Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000005871 repellent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 210000005005 sentinel lymph node Anatomy 0.000 description 3
- 230000008054 signal transmission Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000008151 electrolyte solution Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 description 2
- 229950003332 perflubutane Drugs 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 238000003332 Raman imaging Methods 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-M [(2r)-2,3-di(hexadecanoyloxy)propyl] hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)([O-])=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-M 0.000 description 1
- FYNQLEXETFCEAY-UHFFFAOYSA-N [Gd+3].[Au+3] Chemical compound [Gd+3].[Au+3] FYNQLEXETFCEAY-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002101 nanobubble Substances 0.000 description 1
- 239000002091 nanocage Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002073 nanorod Substances 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- CEYGNZMCCVVXQW-UHFFFAOYSA-N phosphoric acid;propane-1,2-diol Chemical compound CC(O)CO.OP(O)(O)=O CEYGNZMCCVVXQW-UHFFFAOYSA-N 0.000 description 1
- 238000010895 photoacoustic effect Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000128 polypyrrole Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002207 thermal evaporation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000032665 vasculature development Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/44—Constructional features of the ultrasonic, sonic or infrasonic diagnostic device
- A61B8/4416—Constructional features of the ultrasonic, sonic or infrasonic diagnostic device related to combined acquisition of different diagnostic modalities, e.g. combination of ultrasound and X-ray acquisitions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
- A61B5/0035—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for acquisition of images from more than one imaging mode, e.g. combining MRI and optical tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0093—Detecting, measuring or recording by applying one single type of energy and measuring its conversion into another type of energy
- A61B5/0095—Detecting, measuring or recording by applying one single type of energy and measuring its conversion into another type of energy by applying light and detecting acoustic waves, i.e. photoacoustic measurements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/46—Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient
- A61B8/461—Displaying means of special interest
- A61B8/463—Displaying means of special interest characterised by displaying multiple images or images and diagnostic data on one display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agents, e.g. microbubbles introduced into the bloodstream
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/52—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/5215—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data
- A61B8/5238—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data for combining image data of patient, e.g. merging several images from different acquisition modes into one image
- A61B8/5246—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data for combining image data of patient, e.g. merging several images from different acquisition modes into one image combining images from the same or different imaging techniques, e.g. color Doppler and B-mode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/52—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/5215—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data
- A61B8/5238—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data for combining image data of patient, e.g. merging several images from different acquisition modes into one image
- A61B8/5261—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data for combining image data of patient, e.g. merging several images from different acquisition modes into one image combining images from different diagnostic modalities, e.g. ultrasound and X-ray
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/005—Devices for introducing or retaining media, e.g. remedies, in cavities of the body for contrast media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Acoustics & Sound (AREA)
- Epidemiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
Abstract
Description
도 2의 (a)는 고정된 메틸렌블루 농도(15 mM)에서 마이크로버블의 농도가 변화할 때의 메틸렌블루로 착색된 마이크로버블 수용액의 광음향 이미징을 보여주고, (b)는 고정된 메틸렌블루 농도(15 mM)에서 마이크로버블의 농도가 변화할 때의 메틸렌블루로 착색된 마이크로버블 수용액의 초음파 이미징을 보여주고, (c)는 정량화된 광음향 신호 대 마이크로버블 농도의 관계를 보여주고, (d)는 정량화된 초음파 신호 대 마이크로버블 농도의 관계를 보여주고, (e)는 샘플들의 사진이며, (f)는 6 개의 샘플의 마이크로버블과 메틸렌블루의 농도를 보여준다.
도 3의 (a)는 고정된 마이크로버블 농도(0.1 mg/ml)에서 메틸렌블루의 농도가 변화할 때의 메틸렌블루로 착색된 마이크로버블의 수용액에 대한 광음향 이미징을 보여주고, (b)는 고정된 마이크로버블 농도(0.1 mg/ml)에서 메틸렌블루의 농도가 변화할 때의 메틸렌블루로 착색된 마이크로버블의 수용액에 대한 초음파 이미징을 보여주고, (c)는 정량화된 광음향 신호 대 메틸렌블루 농도의 관계를 보여주고, (d)는 정량화된 초음파 신호 대 메틸렌블루 농도의 관계를 보여주고, (e)는 샘플들의 사진이며, (f)는 6 개의 샘플의 메틸렌블루와 마이크로버블의 농도를 보여준다.
도 4의 (a)는 초음파 처리 전과 후의 메틸렌블루로 착색된 마이크로버블의 수용액에 대한 광음향 이미징을 보여주고, (b)는 초음파 처리 전과 후의 메틸렌블루로 착색된 마이크로버블의 수용액에 대한 초음파 이미징을 보여주고, (c)는 샘플들의 사진이며, (d)는 초음파 처리 전과 후의 정량화된 광음향 및 초음파 신호를 보여준다.
도 5의 (a)는 임상용 초음파 어레이에 의하여 발생된 고전압 초음파의 인가 전의 메틸렌블루로 착색된 마이크로버블의 수용액에 대한 광음향 이미지를 보여주고, (b)는 인가 1 분 후의 광음향 이미지를 보여주고, (c)는 10 분 후의 광음향 이미지를 보여주고, (d)는 정량화된 광음향 신호 대 초음파 인가 시간의 관계를 보여준다.
도 6은, 본 개시의 다른 측면에 따라 제공되는 결합된 광음향 및 초음파 진단 장치의 일 구현예의 구성을 도식적으로 보여주는 블록도이다.
도 7은, 도 6의 결합된 광음향 및 초음파 진단 장치의 일 구현예의 트랜스듀서의 구성을 도식적으로 보여주는 블록도이다.
도 8은, 본 개시의 일 측면에 따라 제공되는 결합된 광음향 및 초음파 진단 방법의 일 구현예를 도식적으로 보여주는 흐름도이다.
Claims (21)
- 대상체로 레이저 신호를 방출하는 레이저 송신부;
상기 대상체로 낮은 MI를 갖는 제1 초음파 신호를 방출하고 상기 제1 초음파 신호를 대상체 내의 마이크로버블이 반사하여 생성되는 에코 신호를 검출하며, 상기 대상체로 높은 MI를 갖는 제2 초음파 신호를 방출하여 상기 마이크로버블이 터져 마이크로버블 파편이 생성되도록 하며, 그리고, 상기 레이저 신호가 상기 마이크로버블 파편을 자극하여 생성되는 광음향 신호를 검출하는 초음파 신호 송수신부;
상기 광음향 신호에 기초하여 광음향 영상을 생성하고 상기 에코 신호에 기초하여 초음파 영상을 생성하는 영상 처리부; 및
상기 광음향 영상 및 상기 초음파 영상을 표시하는 표시부;를 포함하는,
결합된 광음향 및 초음파 진단 장치의 사용 방법으로서,
상기 사용 방법은
상기 에코 신호를 검출한 후, 상기 에코 신호에 기초하여 생성된 초음파 영상을 표시하는 단계; 및
상기 광음향 신호에 기초하여 생성된 광음향 영상을 표시하는 단계;를 포함하고,
상기 낮은 MI는 상기 마이크로버블이 깨지지 않을 정도로 낮은 MI이고,
상기 높은 MI는 상기 마이크로버블이 터질 정도로 높은 MI이고,
상기 마이크로버블은
염료로 착색된 지질 쉘; 및
상기 지질 쉘의 내부를 채우는 충전 가스;를 포함하고,
상기 지질을 수화하는데 사용되는 염료 용액 중의 염료의 농도는 0.5 mM 내지 20 mM이며,
상기 염료는 아주레 블루(Azure blue), 에반스 블루(Evans blue), 인도시아닌 그린(idocyanine green), 브릴리안트 블루(brilliant blue), 나일 블루(nile blue), 메틸렌 블루(methylene blue), 또는 이들의 조합인,
결합된 광음향 및 초음파 진단 장치의 사용 방법. - 제 1 항에 있어서, 상기 제1 초음파 신호가 0.5 미만의 낮은 MI를 갖는 것을 특징으로 하는 결합된 광음향 및 초음파 진단 장치의 사용 방법.
- 삭제
- 제 1 항에 있어서, 상기 제2 초음파 신호는 0.5 내지 1.9 범위의 높은 MI를 갖는 것을 특징으로 하는 결합된 광음향 및 초음파 진단 장치의 사용 방법.
- 삭제
- 삭제
- 삭제
- 제 1 항에 있어서, 상기 염료는 500 nm 내지 1,300 nm 범위의 파장을 갖는 입사광을 흡수하는 것을 특징으로 하는 결합된 광음향 및 초음파 진단 장치의 사용 방법.
- 삭제
- 삭제
- 제 1 항에 있어서, 상기 지질을 수화하는데 사용되는 염료 용액 중의 염료의 농도가 15 mM인 것을 특징으로 하는 결합된 광음향 및 초음파 진단 장치의 사용 방법.
- 제 1 항에 있어서, 상기 염료는 메틸렌 블루이고, 상기 지질을 수화하는데 사용되는 염료 용액 중의 염료의 농도는 0.5 mM 내지 20 mM인 것을 특징으로 하는 결합된 광음향 및 초음파 진단 장치의 사용 방법.
- 제 1 항에 있어서, 상기 염료는 메틸렌 블루이고, 상기 지질을 수화하는데 사용되는 염료 용액 중의 염료의 농도는 10 mM 내지 20 mM인 것을 특징으로 하는 결합된 광음향 및 초음파 진단 장치의 사용 방법.
- 제 1 항에 있어서, 상기 지질은 인지질(phospholipid)을 포함하는 것을 특징으로 하는 결합된 광음향 및 초음파 진단 장치의 사용 방법.
- 제 14 항에 있어서, 상기 인지질은 1,2-디팔미토일-sn-글리세로-3-포스파티드산(1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid : DPPA); 1,2-디팔미토일-sn-글리세로-3-포스파티딜콜린(1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine : DPPC); 1,2-디스테아로일-sn-글리세로-3-포스포콜린(1,2-distearoyl-sn-glycero-3-phosphocholine : DSPC); 1,2-디미리스토일-sn-글리세로-3-포스포콜린(1,2-dimyristoyl-sn-glycero-3-phosphocholine : DMPC); 1,2-디베헤노일-sn-글리세로-3-포스포콜린(1,2-dibehenoyl-sn-glycero-3-phosphocholine : DBPC); 1,2-디아라키도일-sn-글리세로-3-포스파티딜콜린(1,2-diarachidoyl-sn-glycero-3-phosphatidylcholine : DAPC); 1,2-디리그노세로일-sn-글리세로-3-포스파티딜콜린(1,2-dilignoceroyl-sn-glycero-3-phosphatidylcholine : DLgPC); 1,2-디팔미토일-sn-글리세로-3-[포스포-rac-(1-글리세롤)](1,2-dipalmitoyl-sn-glycero-3-[phosphor-rac-(1-glycerol)] : DPPG); 또는 이들의 혼합물을 포함하는 것을 특징으로 하는 결합된 광음향 및 초음파 진단 장치의 사용 방법.
- 제 1 항에 있어서, 상기 쉘의 입자 크기는 0.5 ㎛ 내지 10 ㎛인 것을 특징으로 하는 결합된 광음향 및 초음파 진단 장치의 사용 방법.
- 제 1 항에 있어서, 상기 쉘의 벽 두께는 1 nm 내지 200 nm인 것을 특징으로 하는 결합된 광음향 및 초음파 진단 장치의 사용 방법.
- 제 1 항에 있어서, 상기 충전 가스는 생물학적으로 비활성인 가스인 것을 특징으로 하는 결합된 광음향 및 초음파 진단 장치의 사용 방법.
- 제 1 항에 있어서, 상기 충전 가스는, 과불화탄소(perfluorocarbon), 황 헥사플로오라이드(sulphur hexafluoride), 과불화메탄(perfluoromethane), 과불화에탄(perfluoroethane), 과불화프로판(perfluoropropane), 과불화부탄(perfluorobutane), 과불화펜탄(perfluoropentane), 과불화헥산(perfluorohexane), 과불화헵탄(perfluoroheptane), 과불화옥탄(perfluorooctane), 과불화노난(perfluorononane), 과불화데칸(perluorodecane), 과불화벤젠(perfuorobenzene), 과불화트리에틸아민(perfluorotriethylamine), 과불화옥틸브로마이드(perfluorooctylbromide), 또는 이들의 혼합물을 포함하는 것을 특징으로 하는 결합된 광음향 및 초음파 진단 장치의 사용 방법.
- 삭제
- 결합된 광음향 및 초음파 진단 장치로서, 상기 결합된 광음향 및 초음파 진단 장치는,
대상체로 레이저 신호를 방출하는 레이저 송신부;
상기 대상체로 낮은 MI를 갖는 제1 초음파 신호를 방출하고 상기 제1 초음파 신호를 대상체 내의 마이크로버블이 반사하여 생성되는 에코 신호를 검출하며, 상기 대상체로 높은 MI를 갖는 제2 초음파 신호를 방출하여 상기 마이크로버블이 터져 마이크로버블 파편이 생성되도록 하며, 그리고, 상기 레이저 신호가 상기 마이크로버블 파편을 자극하여 생성되는 광음향 신호를 검출하도록 구성된 초음파 신호 송수신부;
상기 광음향 신호에 기초하여 광음향 영상을 생성하고 상기 에코 신호에 기초하여 초음파 영상을 생성하는 영상 처리부; 및
상기 광음향 영상 및 상기 초음파 영상을 표시하는 표시부;를 포함하고,
상기 낮은 MI는 상기 마이크로버블이 깨지지 않을 정도로 낮은 MI이고,
상기 높은 MI는 상기 마이크로버블이 터질 정도로 높은 MI이고,
상기 마이크로버블은
염료로 착색된 지질 쉘; 및
상기 지질 쉘의 내부를 채우는 충전 가스;를 포함하고,
상기 지질을 수화하는데 사용되는 염료 용액 중의 염료의 농도는 0.5 mM 내지 20 mM이며,
상기 염료는 아주레 블루(Azure blue), 에반스 블루(Evans blue), 인도시아닌 그린(idocyanine green), 브릴리안트 블루(brilliant blue), 나일 블루(nile blue), 메틸렌 블루(methylene blue), 또는 이들의 조합인,
결합된 광음향 및 초음파 진단 장치.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130085759A KR102255403B1 (ko) | 2013-07-21 | 2013-07-21 | 결합된 광음향 및 초음파 진단 장치 및 방법 |
PCT/KR2014/006568 WO2015012540A1 (en) | 2013-07-21 | 2014-07-18 | Apparatus and method for combined photoacoustic and ultrasound diagnosis |
EP14829213.9A EP3024393A4 (en) | 2013-07-21 | 2014-07-18 | Apparatus and method for combined photoacoustic and ultrasound diagnosis |
US14/337,204 US10639009B2 (en) | 2013-07-21 | 2014-07-21 | Apparatus and method for combined photoacoustic and ultrasound diagnosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130085759A KR102255403B1 (ko) | 2013-07-21 | 2013-07-21 | 결합된 광음향 및 초음파 진단 장치 및 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150010909A KR20150010909A (ko) | 2015-01-29 |
KR102255403B1 true KR102255403B1 (ko) | 2021-05-25 |
Family
ID=52344117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130085759A Expired - Fee Related KR102255403B1 (ko) | 2013-07-21 | 2013-07-21 | 결합된 광음향 및 초음파 진단 장치 및 방법 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10639009B2 (ko) |
EP (1) | EP3024393A4 (ko) |
KR (1) | KR102255403B1 (ko) |
WO (1) | WO2015012540A1 (ko) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6494364B2 (ja) * | 2015-03-26 | 2019-04-03 | キヤノン株式会社 | 光音響装置 |
JP6590503B2 (ja) | 2015-04-01 | 2019-10-16 | キヤノン株式会社 | 光音響装置および情報取得装置 |
KR20160142199A (ko) * | 2015-06-02 | 2016-12-12 | 삼성메디슨 주식회사 | 광음향 영상화를 위한 조영 조성물 및 그를 사용한 광음향 영상화하는 방법 |
CN107582096A (zh) * | 2016-07-08 | 2018-01-16 | 佳能株式会社 | 用于获取信息的装置、方法和存储介质 |
US10589129B2 (en) * | 2016-09-14 | 2020-03-17 | Insightec, Ltd. | Therapeutic ultrasound with reduced interference from microbubbles |
EP3309625B1 (fr) * | 2016-10-13 | 2020-07-29 | Nivarox-FAR S.A. | Spiral destiné à être fixé par une rondelle élastique |
US20180156755A1 (en) * | 2016-12-01 | 2018-06-07 | Electronics And Telecommunications Research Institute | Apparatus for biomaterial and method of detecting biomaterial |
KR20180075223A (ko) | 2016-12-26 | 2018-07-04 | 삼성메디슨 주식회사 | 광 음향 영상 진단 장치 및 제어방법 |
US11554049B2 (en) | 2017-10-25 | 2023-01-17 | Lutronic Vision Inc. | Distributed acoustic detector system |
KR102232468B1 (ko) * | 2019-02-28 | 2021-03-25 | 서강대학교산학협력단 | 초음파 영상장치 및 초음파 영상장치의 동작방법 |
CN110152024A (zh) * | 2019-06-05 | 2019-08-23 | 深圳市人民医院 | 一种超声与磁共振双模态靶向纳米粒造影剂及其制备方法 |
CN111729188B (zh) * | 2020-06-24 | 2023-07-14 | 南京超维景生物科技有限公司 | 超声引导的载药微泡递送方法及装置 |
KR102398743B1 (ko) | 2020-09-03 | 2022-05-16 | 충남대학교병원 | 초음파유도 마이크로버블을 포함하는 배뇨장애 치료제 조성물 |
US11840919B2 (en) * | 2021-01-04 | 2023-12-12 | Saudi Arabian Oil Company | Photoacoustic nanotracers |
AU2023217725A1 (en) * | 2022-02-09 | 2024-08-15 | Lantheus Medical Imaging, Inc. | Gas nano/micro-bubble compositions and uses thereof |
CN115128299B (zh) * | 2022-08-31 | 2022-12-27 | 之江实验室 | 一种测量非透明流场的光声粒子图像测速系统和方法 |
KR20240043557A (ko) * | 2022-09-27 | 2024-04-03 | 국립부경대학교 산학협력단 | 광음향 영상 및 초음파 영상의 합성 영상 입력장치 및 그 방법 |
WO2024085589A1 (ko) * | 2022-10-17 | 2024-04-25 | 울산과학기술원 | 광음향-초음파 프로브용 전기 회로망과 이를 구비하는 광음향-초음파 프로브 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020151792A1 (en) | 1998-02-06 | 2002-10-17 | Conston Stanley R. | Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility |
US20070092447A1 (en) * | 2004-05-14 | 2007-04-26 | General Electric Company | Contrast agent for combined modality imaging and methods and systems thereof |
US20080008658A1 (en) | 2004-10-08 | 2008-01-10 | Bracco Imaging Spa | Contrast Agent Formulations for the Visualization of the Lymphatic System |
US20080045865A1 (en) | 2004-11-12 | 2008-02-21 | Hanoch Kislev | Nanoparticle Mediated Ultrasound Therapy and Diagnostic Imaging |
US20100106078A1 (en) | 2007-03-09 | 2010-04-29 | Koninklijke Philips Electronics N.V. | Method of controlling a release of a material carried by ultrasound sensitive particles |
WO2013053042A1 (en) * | 2011-10-13 | 2013-04-18 | University Health Network | Porphyrin-phospholipid conjugate microbubbles and their use as contrast agents. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090156932A1 (en) * | 2007-12-13 | 2009-06-18 | Board Of Trustees Of The University Of Arkansas | Device and method for in vivo flow cytometry using the detection of photoacoustic waves |
JP5470630B2 (ja) * | 2008-08-04 | 2014-04-16 | 学校法人関西医科大学 | X線造影用マイクロバブル造影剤製造装置 |
US20120027679A1 (en) | 2009-10-05 | 2012-02-02 | Canon Kabushiki Kaisha | Contrast agent for photoacoustic imaging and photoacoustic imaging method using the same |
WO2011045734A1 (en) * | 2009-10-16 | 2011-04-21 | Koninklijke Philips Electronics N.V. | Photoacoustic contrast agent based active ultrasound imaging |
EP2654551B1 (en) | 2010-12-22 | 2020-05-27 | Koninklijke Philips N.V. | Photo-acoustic signal enhancement with microbubble-based contrast agents |
-
2013
- 2013-07-21 KR KR1020130085759A patent/KR102255403B1/ko not_active Expired - Fee Related
-
2014
- 2014-07-18 EP EP14829213.9A patent/EP3024393A4/en not_active Withdrawn
- 2014-07-18 WO PCT/KR2014/006568 patent/WO2015012540A1/en active Application Filing
- 2014-07-21 US US14/337,204 patent/US10639009B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020151792A1 (en) | 1998-02-06 | 2002-10-17 | Conston Stanley R. | Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility |
US20070092447A1 (en) * | 2004-05-14 | 2007-04-26 | General Electric Company | Contrast agent for combined modality imaging and methods and systems thereof |
US20080008658A1 (en) | 2004-10-08 | 2008-01-10 | Bracco Imaging Spa | Contrast Agent Formulations for the Visualization of the Lymphatic System |
US20080045865A1 (en) | 2004-11-12 | 2008-02-21 | Hanoch Kislev | Nanoparticle Mediated Ultrasound Therapy and Diagnostic Imaging |
US20100106078A1 (en) | 2007-03-09 | 2010-04-29 | Koninklijke Philips Electronics N.V. | Method of controlling a release of a material carried by ultrasound sensitive particles |
WO2013053042A1 (en) * | 2011-10-13 | 2013-04-18 | University Health Network | Porphyrin-phospholipid conjugate microbubbles and their use as contrast agents. |
Also Published As
Publication number | Publication date |
---|---|
US10639009B2 (en) | 2020-05-05 |
KR20150010909A (ko) | 2015-01-29 |
US20150025373A1 (en) | 2015-01-22 |
EP3024393A4 (en) | 2017-04-26 |
EP3024393A1 (en) | 2016-06-01 |
WO2015012540A1 (en) | 2015-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102255403B1 (ko) | 결합된 광음향 및 초음파 진단 장치 및 방법 | |
Jeon et al. | Methylene blue microbubbles as a model dual-modality contrast agent for ultrasound and activatable photoacoustic imaging | |
US20150023881A1 (en) | Contrast agent for combined photoacoustic and ultrasound imaging | |
Loskutova et al. | Review on acoustic droplet vaporization in ultrasound diagnostics and therapeutics | |
Wheatley et al. | Comparison of in vitro and in vivo acoustic response of a novel 50: 50 PLGA contrast agent | |
EP0907380B1 (en) | Pressure resistant protein microspheres as ultrasonic imaging agents | |
Lin et al. | Optically and acoustically triggerable sub-micron phase-change contrast agents for enhanced photoacoustic and ultrasound imaging | |
JP6263121B2 (ja) | ポルフィリン−リン脂質の結合した微小気泡及びそれらの造影剤としての使用 | |
JP5506998B2 (ja) | 光音響測定装置 | |
CZ28999A3 (cs) | Použití kontrastního prostředku | |
Li et al. | Acoustic characterization and enhanced ultrasound imaging of long‐circulating lipid‐coated microbubbles | |
Desgranges et al. | Micron-sized PFOB liquid core droplets stabilized with tailored-made perfluorinated surfactants as a new class of endovascular sono-sensitizers for focused ultrasound thermotherapy | |
Grillo et al. | Glycerol in oil-based phantom with improved performance for photoacoustic imaging | |
Yoshida et al. | Fluorescence intensity changes depending on viscoelasticity of lipid shell coating microbubbles labeled with an indocyanine green derivative | |
WO2019198461A1 (ja) | 超音波造影及び近赤外蛍光造影の両方が可能な造影剤 | |
US20220288227A1 (en) | Ultrasound Responsive Microbubbles And Related Methods | |
Pellow | Nonlinear nanobubble behaviour for vascular and extravascular applications | |
Larsson et al. | Visualization of multimodal polymer-shelled contrast agents using ultrasound contrast sequences: an experimental study in a tissue mimicking flow phantom | |
Lin | Phase-change contrast agent and its applications in contrast-enhanced ultrasound and photoacoustic imaging | |
Sun | Acoustic characterisation of ultrasound contrast agents at high frequency | |
JP5892833B2 (ja) | 光音響試薬、試薬群、及びその製法 | |
Iradji | Optimization of subharmonic generation from ultrasound contrast agents at high frequency ultrasound | |
Rashid | Image Contrast Enhancement using Poly Vinyl Alcohol Microbubble Response to High MI Ultrasound | |
Lee | High frequency ultrasound backscatter analysis for the detection of early tumour response to radiotherapy and a novel anti-vascular treatment | |
Schrope et al. | polysaccharide alginate, for the microencapsulation of air. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20130721 |
|
N231 | Notification of change of applicant | ||
PN2301 | Change of applicant |
Patent event date: 20130808 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20180719 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20130721 Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200212 Patent event code: PE09021S01D |
|
E90F | Notification of reason for final refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20200918 Patent event code: PE09021S02D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20210223 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20210517 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20210518 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20250227 |